Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Pancreatic Neoplasms 10Ovarian Neoplasms 10Fallopian Tube Neoplasms 10Lung Neoplasms 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 4Esophageal Neoplasms 4Endometrial Neoplasms 4Oropharyngeal Neoplasms 3Mouth Neoplasms 3Melanoma 3Inflammatory Breast Neoplasms 3Hypopharyngeal Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Neoplasms, Squamous Cell 2Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Brenner Tumor 2Adenocarcinoma of Lung 2

Interventions

Taxes 1Hydroxychloroquine 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Untreated Resectable Pancreatic Adenocarcinoma × Taxes × Clear all
NCT04669197 2025-08-15

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

HonorHealth Research Institute

Phase 2 Active not recruiting
19 enrolled
Gastrointestinal

Untreated Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡